MedTrace Logo

Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG

NCT06221553 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-03-30

No results posted yet for this study

Summary

A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cell with IL-7Ra signal targeting B7H3 in children with diffuse intrinsic pontine glioma (DIPG) patients after complete standard treatments.

Conditions

  • DIPG Brain Tumor
  • Diffuse Intrinsic Pontine Glioma

Interventions

BIOLOGICAL

B7H3 specific CAR T cell with IL-7Ra signaling domain

Autologous T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) with additional of IL-7 receptor alpha signalingdomain given via indwelling central nervous system (CNS) catheter

Sponsors & Collaborators

  • King Chulalongkorn Memorial Hospital

    collaborator OTHER

  • Chulalongkorn University

    lead OTHER

Principal Investigators

  • Piti Techavichit, MD · Chulalongkorn University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2026-03-01
Completion
2026-09-01

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06221553 on ClinicalTrials.gov